Intellipharmaceutics Int'l Q2 Loss Widens

(RTTNews) - Intellipharmaceutics International Inc. (IPCI, I.TO), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reported second-quarter net loss of $3.1 million or $0.14 per share, wider than $1.8 million, or $0.09 per share in the comparable quarter last year.

Total revenue for the latest second quarter was $1.48 million. The company did not generate any revenue in the prior year period.

On average, Analysts polled by Thomson Reuters expected the company to report earnings of $0.09 per share and revenues of $3.77 million for the quarter. Analysts' estimates typically exclude special items.